After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way. On Wednesday, the US Food and Drug Administration ...

Tony Wood, Chief Scientific Officer, GSK: “We are pleased with ACIP's recommendation to expand the benefits of RSV immunization to more than 13 million adults aged 50-59 who are at increased risk for ...

Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory ...

A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. This story was originally published on BioPharma Dive. To receive daily news ...

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine ...

GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the expanded use of their ...

According to DataM Intelligence, the Respiratory Syncytial Virus (RSV) Market Size reached USD 1.95 billion in 2024 and is projected to advance to USD 4.54 billion by 2033, expanding at a strong CAGR ...

Real-world effectiveness with the recommended single dose of respiratory syncytial virus (RSV) vaccination dipped in older ...

(RTTNews) - GSK plc (GSK, GSK.L) announced that the FDA has accepted for review an application to extend the indication of Arexvy or respiratory syncytial virus vaccine, adjuvanted to adults aged ...

-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden ...

The FDA identified an estimated 9 excess GBS cases per million doses for Pfizer's Abrysvo and 7 excess cases per million for GSK's Arexvy. Updated warnings stem from Medicare-based studies assessing ...

Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunization 1 RSV causes an estimated 42,000 hospitalizations* each year in adults aged 50-64 years old ...